

Synthesis and reactions of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones

Joana Solovjova,^a Vytas Martynaitis,^a Wolfgang Holzer,^b Sven Mangelinckx,^{c,†}
Norbert De Kimpe,^c and Algirdas Šackus^{a,*}

^a*Institute of Synthetic Chemistry, Kaunas University of Technology, LT-50270 Kaunas, Lithuania*

^b*Department of Drug and Natural Product Synthesis, University of Vienna, Pharmaziezentrum,
A-1090 Vienna, Austria*

^c*Department of Organic Chemistry, Faculty of Bioscience Engineering, Ghent University,
Coupure Links 653, B-9000 Ghent, Belgium*

E-mail: algirdas.sackus@ktu.lt

Dedicated to Professor Henk Van der Plas on the occasion of his 80th anniversary

Abstract

1-Amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones, as previously unknown ring-annelated isoquinolines with a 3-aminoimidazolidin-4-one scaffold, were selectively prepared upon reacting 2-carbamoylmethyl- or 2-ethoxycarbonylmethyl-3,4-dihydroisoquinolinium salts with hydrazine hydrate. Acylation of the primary amino group with benzoyl chlorides, followed by reductive ring cleavage of the annelated 4-imidazolidinone ring and final cyclodehydration of the *N,N'*-diacylhydrazines resulted in the synthesis of 1-methyl-2-(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolines which are of interest due to their potential use as bioisosteres of biologically active *N*-aryl-2-(1-methyl-3,4-dihydro-1*H*-isoquinolin-2-yl)acetamides.

Keywords: Ring annelation, isoquinolines, 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones, hydrazides, 1,3,4-oxadiazoles

Introduction

Due to the natural occurrence and interesting chemical or biological properties of ring-annelated isoquinolines,¹ as exemplified by the tetrahydroisoquinoline antitumor antibiotics,² and lamellarin alkaloids,³ a broad interest in the synthesis of this class of azaheterocyclic compounds


[†] Postdoctoral Fellow of the Research Foundation – Flanders (FWO-Vlaanderen)

exists.⁴ The tricyclic 1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones, which can be prepared via annelation of the imidazolidinone scaffold to 3,4-dihydroisoquinolines,⁵ allows further access to heterocyclic compounds with biological interest such as antidepressant activity.⁶ Recently, we demonstrated that the hydrazides derived from 1-carbamoylmethyl-3*H*-indolinium salts selectively cyclize to 1-amino-1,2,3,9a-tetrahydroimidazo[1,2-*a*]indol-2(9*H*)-ones and that the corresponding six-membered ring systems, that is, 1,2,10,10a-tetrahydro[1,2,4]triazino[4,3-*a*]indol-3(4*H*)-ones, by entering of the terminal NH₂ group into reaction, are not formed.⁷ In an effort to broaden the scope of this regioselective ring-annelation reaction of hydrazides and to further expand the chemical space of ring-fused isoquinoline derivatives, the objective of this work is to investigate the synthesis of the unknown 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones and to study the transformation of the novel cyclic products to 1,3,4-oxadiazoles. Considerable interest in the synthesis of substituted 1,3,4-oxadiazoles exists due to their numerous pharmacological properties, including analgesic, antiinflammatory, anticonvulsive, diuretic, antiemetic, hypnotic and sedative activities.^{8,9} More specific, 2-amino-1,3,4-oxadiazoles act as muscle relaxants¹⁰ and possess antimetabolic activity.¹¹


Results and Discussion

As previously reported, the annelation of the imidazolidine ring to the isoquinoline nucleus starts by reaction of 3,4-dihydroisoquinoline or the corresponding 6,7-dimethoxy derivative with chloroacetamide which affords 2-carbamoylmethyl-3,4-dihydroisoquinolinium chloride **1**.^{5c} It was shown previously that the reaction of 2-carbamoylmethyl-3,4-dihydroisoquinolinium chloride **1** with aqueous potassium hydroxide afforded 10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-one.^{5a} During the present investigations, it was found that heating 2-carbamoylmethyl-3,4-dihydroisoquinolinium chlorides **1** in the presence of hydrazine hydrate regioselectively lead to the formation of five-membered heterocycles, i.e. 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones **3** in good yields, with hydrazines **2** as potential intermediates and without any observation of the corresponding six-membered compounds **4** (Scheme 1). Similarly, 2-ethoxycarbonylmethyl-3,4-dihydroisoquinolinium bromide **6**, prepared by treatment of 1-methyl-3,4-dihydroisoquinoline with ethyl 2-bromoacetate,¹² efficiently reacted with hydrazine hydrate under mild reaction conditions to afford 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones **3** (Scheme 2). The main evidence for the assignment of structures **3a,b** containing the 1-amino-4-imidazolidinone ring, followed from the ¹⁵N NMR data. The ¹⁵N NMR spectrum showed three different N-atoms with chemical shifts at -341.7, -327.0 and -227.0 ppm (for compound **3a**) and -342.1, -327.2 and -226.6 (for compound **3b**). In ¹⁵N DEPT experiments without ¹H-decoupling the central ¹⁵N NMR resonance (~ -327 ppm) showed a triplet multiplicity (¹*J* = 68.9 Hz), thus unequivocally indicating the presence of an NH₂ moiety. This definitely ruled out the corresponding six-membered structure **4**, for which two NH substructures and a tertiary nitrogen

atom would be expected. Moreover, the $^{15}\text{N},^1\text{H}$ -HMBC spectrum of compound **3a** exhibited a clear correlation between the nitrogen atom with the largest chemical shift (N-1, $\delta = -227.0$ ppm) and the methyl protons of 10b-CH₃ ($\delta = 1.70$ ppm), what seems improbable with structure **4** where the involved nuclei would be separated by four bonds and thus no correlation is expected. In addition, the ^1H NMR spectra of compounds **3** contained only one sharp signal (at 3.97 ppm for **3a** and at 3.98 ppm for **3b**) with a relative intensity of two protons attributed to the NH₂-function. In contrast, for the corresponding six-membered structure **4**, two different NH-signals each with a relative intensity of one proton would be expected.



Scheme 1




Scheme 2

The assignments presented in Figures 1(a) and 2(a) were based on the combined application of standard NMR techniques such as NOE-difference (Figure 1(b) and 2(b)), NOESY, APT, DEPT, HSQC, HMBC and long-range INEPT spectra with selective excitation.¹³


As in the case of 1-amino-1,2,3,9a-tetrahydroimidazo[1,2-*a*]indol-2(9*H*)-ones,⁷ no other ring-chain tautomeric forms of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones (**3a,b**) were visible by ^1H and ^{13}C NMR in CDCl₃ or DMSO-*d*₆. Due to higher substitution and thereby higher conjugation, the tricyclic compound **3** is expected to be more favored than the

1,2,3,4-tetrahydroisoquinolines **9a-f** under modified Appel conditions.¹⁵ The 2-(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline moiety was present as a structural feature in compounds acting as urotensin-II receptor antagonists.¹⁶ 1,3,4-Oxadiazoles are used as bioisosteres of amide functionalities in bioactive compounds,¹⁷ and, therefore, congeners **9** have potential for bioisosteric replacement of *N*-aryl-2-(1-methyl-3,4-dihydro-1*H*-isoquinolin-2-yl)acetamides which act as antagonists of SNS sodium channels,¹⁸ inhibitors of voltage-gated sodium channels,¹⁹ and antiprotozoal agents.²⁰

The exocyclic amino group in compounds **3** reacted with aromatic aldehydes by heating in ethanol in the presence of catalytic amounts of piperidine and afforded the corresponding hydrazones **10a-c**, albeit in low yields. Compounds **10** could also be forced to reductive ring opening by reaction with sodium borohydride in THF to give acylated hydrazones **11** (Scheme 4).²¹



Scheme 3



Scheme 4

Conclusions

2-Carbamoylmethyl- or 2-ethoxycarbonylmethyl-3,4-dihydroisoquinolinium salts regioselectively cyclised to 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones upon treatment with hydrazine hydrate. The latter heterocyclic compounds occurred as single tautomeric forms and were the first ring-annulated isoquinolines with a 3-aminoimidazolidin-4-one scaffold. The primary amino group was used as a handle via arylation, reductive ring cleavage and cyclodehydration for further transformation to new 1,3,4-oxadiazoles which have potential as bioisosteres of biologically active *N*-aryl-2-(3,4-dihydro-1*H*-isoquinolin-2-yl)acetamides.

Experimental Section

General Procedures. Melting points were determined in open capillary tubes with a Büchi B-540 melting point apparatus and are uncorrected. Infrared spectra were recorded on a Perkin Elmer Spectrum One spectrometer using potassium bromide pellets. ¹H NMR spectra were recorded at 300 MHz on a Varian Unity Inova spectrometer and at 500 MHz on a Bruker Avance 500 spectrometer; ¹³C NMR spectra were registered at 75 and 125 MHz, respectively. Chemical shifts, expressed in ppm, were relative to tetramethylsilane (TMS). ¹⁵N NMR spectra (50.69 MHz) were obtained on a Bruker Avance 500 spectrometer using a 'directly' detecting broadband observe probe and were referenced against neat, external nitromethane (coaxial capillary). Mass spectra were recorded on a Agilent 110 (series MS with VL) instrument. Elemental analyses were measured with a CE-440 elemental analyzer, Model 440 CHN/O/S. For thin layer chromatographic (TLC) analyses, Merck precoated TLC plates (silica gel 60 F254) were used.

General procedures for the synthesis of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones 3

Procedure 1. A mixture of 1-methyl-2-carbamoylmethyl-3,4-dihydroisoquinolinium chloride **1** (10 mmol) and hydrazine hydrate (55%, 10 mL) was heated at 70 °C for 5 h. The reaction mixture was cooled to room temperature, 10 ml of water was added and extraction was performed with dichloromethane (5 x 20 mL). The combined extracts were washed with water (25 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated *in vacuo* and the residue was chromatographed on silica gel with hexane/ethyl acetate/methanol 2:4:1 (for **3a**) or dichloromethane/methanol 100:5 (for **3b**) as eluent to yield **3**.

Procedure 2. A mixture of 2-carbamoylmethyl-3,4-dihydroisoquinolinium bromide **6** (10 mmol) and hydrazine hydrate (55%, 10 mL) was stirred at room temperature for 1 h. Water (10 mL) was added and extraction was performed with dichloromethane (5 x 20 mL). The combined extracts were washed with water (25 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated *in vacuo* and the residue was chromatographed on silica gel with hexane/ethyl acetate/methanol 2:4:1 (for **3a**) or dichloromethane/methanol 100:5 (for **3b**) as eluent to yield **3**.

1-Amino-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one (3a). Yield 82% (procedure 1), 88% (procedure 2). Mp 134-135 °C. ¹H NMR (500 MHz, CDCl₃): δ 1.70 (3H, s, CH₃), 2.63 (1H, m, ²J = 16.6 Hz, ³J_{5A} = 4.3 Hz, ³J_{5B} = 4.5 Hz, 6-CH_B), 3.01 (1H, m, ²J = 16.6 Hz, ³J_{5A} = 9.6 Hz, ³J_{5B} = 4.6 Hz, 6-CH_A), 3.09 (1H, m, ²J = 13.4 Hz, ³J_{6A} = 4.6 Hz, ³J_{6B} = 4.5 Hz, 5-CH_B), 3.21 (1H, m, ²J = 13.4 Hz, ³J_{6A} = 9.6 Hz, ³J_{6B} = 4.3 Hz, 5-CH_A), 3.58 (1H, A-part of an AB-system, ²J = 15.0 Hz, 3-CH_A), 3.46 (1H, B-part of an AB-system, ²J = 15.0 Hz, 3-CH_B), 3.97 (2H, s, NH₂), 7.10 (1H, m, 7-CH), 7.21 (2H, m, 8-CH, 9-CH), 7.85 (1H, m, 10-CH). ¹³C NMR (125 MHz, CDCl₃): δ 24.1 (6-CH₂), 26.4 (10b-CH₃), 44.5 (5-CH₂), 51.0 (3-CH₂), 78.3 (10b-C), 126.4 (9-C), 127.4 (10-C), 127.5 (8-C), 128.8 (7-C), 133.4 (6a-C), 136.8 (10a-C), 169.7 (2-C). ¹⁵N NMR (50 MHz, CDCl₃): -341.7 (4-N), -327.0 (t, J = 68.9 Hz, NH₂), -227.0 (1-N). IR (KBr, cm⁻¹): ν_{N-H} = 3300; ν_{N-H} = 3173; ν_{C=O} = 1716. MS *m/z* (%): 218 (M + H⁺, 100). Anal. Calcd for C₁₂H₁₅N₃O: C 66.34; H 6.96; N 19.34. Found: C 65.99; H 6.36; N 19.54.

1-Amino-8,9-dimethoxy-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isquinolin-2(3H)-one (3b). Yield 90% (procedure 1), 71% (procedure 2). Mp 123-124 °C. ¹H NMR (500 MHz, CDCl₃): δ 1.66 (3H, s, CH₃), 2.51 (1H, m, ²J = 16.4 Hz, ³J_{5A} = 4.3 Hz, ³J_{5B} = 4.5 Hz, 6-CH_B), 2.92 (1H, m, ²J = 16.4 Hz, ³J_{5A} = 9.6 Hz, ³J_{5B} = 4.6 Hz, 6-CH_A), 3.06 (1H, m, ²J = 13.4 Hz, ³J_{6A} = 4.6 Hz, ³J_{6B} = 4.5 Hz, 5-CH_B), 3.18 (1H, m, ²J = 13.4 Hz, ³J_{6A} = 9.6 Hz, ³J_{6B} = 4.3 Hz, 5-CH_A), 3.53 (1H, A-part of an AB-system, ²J = 15.0 Hz, 3-CH_A), 3.42 (1H, B-part of an AB-system, ²J = 15.0 Hz, 3-CH_B), 3.83 (3H, s, 8-OCH₃), 3.85 (3H, s, 9-OCH₃), 3.98 (2H, s, NH₂), 6.53 (1H, m, 7-CH), 7.38 (1H, m, 10-CH). ¹³C NMR (125 MHz, CDCl₃): δ 23.4 (6-CH₂), 26.4 (10b-CH₃), 44.3 (5-CH₂), 50.8 (3-CH₂), 55.7 (8-OCH₃), 55.9 (9-OCH₃), 78.1 (10b-C), 110.0 (10-C), 110.7 (7-C), 125.6 (6a-C), 128.9 (10a-C), 147.3 (9-C), 148.3 (8-C), 169.7 (2-C). ¹⁵N NMR (50 MHz, CDCl₃): -342.1 (4-N), -327.2 (t, J = 68.9 Hz, NH₂), -226.6 (1-N). IR (KBr, cm⁻¹): ν_{N-H} = 3317; ν_{N-H} = 3202; ν_{C=O} = 1712. MS *m/z* (%): 278 (M + H⁺, 100). Anal. Calcd for C₁₄H₁₉N₃O₃: C 60.63; H 6.91; N 15.15. Found: C 60.86; H 6.76; N 14.80.

General procedure for the acylation of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones **3 with benzoyl chlorides**

To a stirred solution of **3** (10 mmol) in dry acetonitrile (7.5 mL), a solution of benzoyl chloride (11 mmol) in dry acetonitrile (10 mL) was added dropwise at room temperature and the mixture was stirred for 1 hour. The formed crystals were separated by filtration and dissolved in water (25 mL). Solid NaHCO₃ was added in portions to basify the mixture to pH 8-9. The mixture was extracted with dichloromethane (3 × 25 mL), the combined extracts were washed with water (25 mL) and dried over anhydrous sodium sulfate. The solvent was evaporated *in vacuo* and the residue was purified by flash chromatography with acetone/hexane 1:1 (for **7a-c**) or dichloromethane/methanol 9:1 (for **7d-f**) to give the corresponding *N,N'*-diacylhydrazines **7**.

***N*-(10b-Methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-yl)benzamide (7a)**. Yield 85%. Mp 82 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.69 (3H, s, 10b-CH₃), 2.63-3.08 (5H, m, 2×CH₂ and CH(H)), 3.59 (1H, d, *J* = 15.8 Hz, CH(H)), 7.09-7.77 (9H, m, aromatic protons), 9.21 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 24.8 (CH₂), 26.2 (10b-CH₃), 45.4 (CH₂), 51.4 (CH₂), 80.3 (C), 126.5, 127.1, 127.5 (2×CH), 127.8, 128.4 (2×CH), 128.8, 131.1, 132.1, 133.6 (Ar-C), 166.1 (C=O), 170.3 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3250; ν_{C=O} = 1723; ν_{C=O} = 1686. MS *m/z* (%): 322 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₉N₃O₂: C 71.01; H 5.96; N 13.08. Found: C 71.18; H 5.98; N 12.71.

3-Chloro-*N*-(10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-yl)benzamide (7b). Yield 67%. Mp 162 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.69 (3H, s, 10b-CH₃), 2.64-3.09 (5H, m, 2×CH₂ and CH(H)), 3.60 (1H, d, *J* = 15.8 Hz, CH(H)), 7.10-7.69 (8H, m, aromatic protons), 9.47 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 24.6 (CH₂), 26.1 (10b-CH₃), 45.3 (CH₂), 51.3 (CH₂), 80.4 (C), 125.1, 126.6, 127.1, 127.9, 128.1, 128.8, 129.7, 132.2, 132.4, 133.5, 134.6 (Ar-C), 164.4 (C=O), 170.3 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3193; ν_{C=O} = 1721; ν_{C=O} = 1691. MS *m/z* (%): 356/58 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈ClN₃O₂: C 64.13; H 5.10; N 11.81. Found: C 64.50; H 5.07; N 11.43.

4-Fluoro-*N*-(10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-yl)benzamide (7c). Yield 96%. Mp 94 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.67 (3H, s, 10b-CH₃), 2.59-3.12 (5H, m, 2×CH₂ and CH(H)), 3.55 (1H, d, *J* = 15.8 Hz, CH(H)), 6.89 – 7.80 (8H, m, aromatic protons), 9.46 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 24.5 (CH₂), 26.1 (10b-CH₃), 44.9 (CH₂), 51.1 (CH₂), 80.3 (C), 115.4 (d, *J* = 21.9 Hz, Ph 3,5-C), 126.6, 126.9 (d, *J* = 2.5 Hz, 1-C), 127.2, 127.9, 128.8, 129.9 (d, *J* = 9.1 Hz, Ph 2,6-C), 133.5, 164.9 (d, *J* = 252.9 Hz, Ph 4-C), 164.7 (C=O), 170.6 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3250; ν_{C=O} = 1722; ν_{C=O} = 1686. MS *m/z* (%): 340 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈FN₃O₂: C 67.24; H 5.35; N 12.38. Found: C 67.63; H 5.57; N 12.15.

***N*-(8,9-Dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-1(5H)-yl)benzamide (7d)**. Yield 74%. Mp 93 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.66 (3H, s, 10b-CH₃), 2.49-3.09 (5H, m, 2×CH₂ and CH(H)), 3.53 (1H, d, *J* = 15.5 Hz, CH(H)), 3.77 (3H, s, CH₃), 3.86 (3H, s, CH₃), 6.54 (1H, s, C₇-H), 6.85 (1H, s, C₁₀-H), 7.18-7.24 (2H, m, C₃-H and

C₅-H), 7.32-7.37 (1H, m, C₄-H), 7.74-7.76 (2H, m, C₂-H and C₆-H), 9.63 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 24.0 (CH₂), 26.3 (10b-CH₃), 45.2 (CH₂), 50.9 (CH₂), 55.9 (CH₃), 56.1 (CH₃), 80.4 (C), 109.9, 110.9, 125.7, 127.7 (2×CH), 128.7 (2×CH), 130.9, 132.4, 147.7, 148.7 (Ar-C), 166.3 (C=O), 170.9 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3245; ν_{C=O} = 1720; ν_{C=O} = 1684. MS *m/z* (%): 382 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₃N₃O₄: C 66.13; H 6.08; N 11.02. Found: C 66.49; H 6.46; N 11.04.

3-Chloro-*N*-(8,9-dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-1(5*H*)-yl)benzamide (7e). Yield 95%. Mp 105 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.64 (3H, s, 10b-CH₃), 2.48-3.13 (5H, m, 2×CH₂ and CH(H)), 3.53 (1H, d, *J* = 15.6 Hz, CH(H)), 3.79 (3H, s, CH₃), 3.86 (3H, s, CH₃), 6.53 (1H, s, C₇-H), 6.81 (1H, s, C₁₀-H), 7.15-7.21 (1H, m, C₅-H), 7.34-7.38 (1H, m, C₄-H), 7.67-7.69 (2H, m, C₂-H, C₆-H), 9.87 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 23.5 (CH₂), 25.9 (10b-CH₃), 44.7 (CH₂), 50.4 (CH₂), 55.6 (CH₃), 55.8 (CH₃), 80.2 (C), 109.6, 110.7, 124.8, 125.4, 128.2, 129.6, 132.1, 132.2, 134.7, 147.4, 148.5 (Ar-C), 164.4 (C=O), 170.8 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3194; ν_{C=O} = 1721; ν_{C=O} = 1686. MS *m/z* (%): 416/18 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₂ClN₃O₄: C 60.65; H 5.33; N 10.10. Found: C 60.32; H 5.88; N 9.86.

4-Fluoro-*N*-(8,9-dimethoxy-10b-methyl-2-oxo-2,3,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-1(5*H*)-yl)benzamide (7f). 76% yield. Mp 111 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.64 (3H, s, 10b-CH₃), 2.47-3.14 (5H, m, 2×CH₂ and CH(H)), 3.51 (1H, d, *J* = 15.6 Hz, CH(H)), 3.79 (3H, s, CH₃), 3.86 (3H, s, CH₃), 6.53 (1H, s, C₇-H), 6.81 (1H, s, C₁₀-H), 6.86-6.91 (2H, m, C₃-H and C₅-H), 7.77-7.82 (2H, m, C₂-H and C₆-H), 9.81 (1H, s, NH). ¹³C NMR (75 MHz, CDCl₃): δ 23.4 (CH₂), 25.8 (10b-CH₃), 44.5 (CH₂), 50.3 (CH₂), 55.6 (CH₃), 55.8 (CH₃), 80.1 (C), 109.6, 110.6, 115.4 (d, *J* = 21.9 Hz, 2×CH), 125.3, 126.7 (d, *J* = 2.4 Hz, Ph 1-C), 129.9 (br d, *J* = 8.9 Hz, Ph 2,6-C), 147.4, 148.4, 164.9 (d, *J* = 253.2 Hz, Ph 4-C) (Ar-C), 164.7 (C=O), 170.9 (C=O). IR (KBr, cm⁻¹): ν_{N-H} = 3250; ν_{C=O} = 1718; ν_{C=O} = 1685. MS *m/z* (%): 400 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₂FN₃O₄: C 63.15; H 5.55; N 10.52. Found: C 63.41; H 5.83; N 10.75.

General procedure for the reduction of *N*-substituted 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-ones (7a-f, 10a,b) with sodium borohydride

To a solution of *N*-substituted 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-*a*]isoquinolin-2(3*H*)-one **7** or **10** (1.35 mmol) in 7 mL of dry tetrahydrofuran, sodium borohydride (0.153 g, 4.05 mmol) was added. The mixture was heated at 70 °C for one hour, then cooled to room temperature, poured into water (30 mL) and extracted with dichloromethane (3 × 20 mL). The combined extracts were washed with water (20 mL) and dried over sodium sulfate. After filtration, the solvent was removed under reduced pressure and the residue purified by flash chromatography on silica gel with acetone/hexane 1:1 (for **8a-f**) or acetone/hexane 1:3 (for **11a,b**) to obtain the various hydrazines **8** and **11**.

***N*'-[2-(1-Methyl-3,4-dihydro-2(1*H*)-isoquinolinyl)acetyl]benzohydrazide (8a).** Yield 65%. Mp 115 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.33 (3H, d, *J* = 6.6 Hz, CH₃), 2.71-3.10 (4H, m, 2×CH₂), 3.27 (1H, d, *J* = 15.6 Hz, CH(H)), 3.37 (1H, d, *J* = 15.6 Hz, CH(H)), 3.95 (1H, q, *J* =

6.6 Hz, CH), 6.10-7.91 (9H, m, aromatic protons), 9.76 (1H, s, NH), 10.39 (1H, s, NH). ^{13}C NMR (75 MHz, DMSO- d_6): δ 19.5 (CH₃), 27.3 (CH₂), 44.8 (CH₂), 56.3 (CH), 56.5 (CH₂), 125.6, 125.8, 127.2, 127.5 (2 \times CH), 128.5 (2 \times CH), 128.6, 131.8, 132.5, 133.9, 139.8 (Ar-C), 165.3 (C=O), 169.6 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3172$; $\nu_{\text{C=O}} = 1698$; $\nu_{\text{C=O}} = 1645$. MS m/z (%): 324 (M + H⁺, 100). Anal. Calcd for C₁₉H₂₁N₃O₂: C 70.57; H 6.55; N 12.99. Found: C 70.19; H 6.67; N 12.77.

3-Chloro-*N'*-[(1-methyl-3,4-dihydro-2(1*H*)-isoquinolinyl)acetyl]benzohydrazide (8b). Yield 85%. Mp 149 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 1.32 (3H, d, $J = 6.6$ Hz, CH₃), 2.69-3.09 (4H, m, 2 \times CH₂), 3.28 (1H, d, $J = 15.6$ Hz, CH(H)), 3.37 (1H, d, $J = 15.6$ Hz, CH(H)), 3.94 (1H, q, $J = 6.6$ Hz, CH), 7.08-7.93 (8H, m, aromatic protons), 9.82 (1H, s, NH), 10.54 (1H, s, NH). ^{13}C NMR (75 MHz, DMSO- d_6): δ 19.5 (CH₃), 27.3 (CH₂), 44.8 (CH₂), 56.3 (CH), 56.6 (CH₂), 125.6, 125.8, 126.2, 127.1, 127.3, 128.6, 130.6, 131.7, 133.3, 133.9, 134.5, 139.8 (Ar-C), 163.9 (C=O), 169.6 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3213$; $\nu_{\text{C=O}} = 1700$; $\nu_{\text{C=O}} = 1646$. MS m/z (%): 358/60 (M + H⁺, 100). Anal. Calcd for C₁₉H₂₀ClN₃O₂: C 63.77; H 5.63; N 11.74. Found: C 64.02; H 5.65; N 11.62.

4-Fluoro-*N'*-[2-(1-methyl-3,4-dihydro-1*H*-isoquinolin-2-yl)acetyl]benzohydrazide (8c). Yield 82%. Mp 106 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 1.32 (3H, d, $J = 6.6$ Hz, CH₃), 2.69-3.10 (4H, m, 2 \times CH₂), 3.27 (1H, d, $J = 15.6$ Hz, CH(H)), 3.37 (1H, d, $J = 15.6$ Hz, CH(H)), 3.94 (1H, q, $J = 6.6$ Hz, CH), 7.07-7.99 (8H, m, aromatic protons), 9.78 (1H, s, NH), 10.44 (1H, s, NH). ^{13}C NMR (75 MHz, DMSO- d_6): δ 19.5 (CH₃), 27.3 (CH₂), 44.8 (CH₂), 56.3 (CH), 56.6 (CH₂), 115.5 (d, $J = 21.9$ Hz, Ph 3,5-C), 125.6, 125.8, 127.1, 128.6, 128.9 (d, $J = 2.8$ Hz, Ph 1-C), 130.2 (d, $J = 9.4$ Hz, Ph 2,6-C), 133.9, 139.8, 164.2 (d, $J = 249.3$ Hz, Ph 4-C), 164.3 (C=O), 169.6 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3252$; $\nu_{\text{C=O}} = 1701$; $\nu_{\text{C=O}} = 1650$. MS m/z (%): 342 (M + H⁺, 100). Anal. Calcd for C₁₉H₂₀FN₃O₂: C 66.85; H 5.91; N 12.31. Found: C 66.48; H 6.16; N 12.30.

***N'*-[2-(6,7-Dimethoxy-1-methyl-3,4-dihydro-1*H*-isoquinolin-2-yl)acetyl]benzohydrazide (8d).** Yield 61%. Mp 69 °C. ^1H NMR (300 MHz, CDCl₃): δ 1.47 (3H, d, $J = 6.6$ Hz, CH₃), 2.65-3.25 (4H, m, 2 \times CH₂), 3.37 (2H, s, CH₂), 3.83 (3H, s, CH₃), 3.84 (3H, s, CH₃), 3.81-3.88 (1H, m, CH), 6.53 (1H, s, C₅-H), 6.58 (1H, s, C₈-H), 7.35-7.40 (2H, m, C₃-H and C₅-H), 7.46-7.51 (1H, m, C₄-H), 7.79-7.82 (2H, m, C₂-H and C₆-H), 9.55 (2H, br s, 2 \times NH). ^{13}C NMR (75 MHz, CDCl₃): δ 20.5 (CH₃), 26.7 (CH₂), 45.2 (CH₂), 55.8 (CH₃), 55.9 (CH₃), 57.0 (CH), 57.2 (CH₂), 109.9, 111.3, 125.2, 127.2 (2 \times CH), 128.5 (2 \times CH), 130.6, 131.3, 132.2, 147.3, 147.5 (Ar-C), 164.7 (C=O), 168.8 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3279$; $\nu_{\text{C=O}} = 1703$; $\nu_{\text{C=O}} = 1657$. MS m/z (%): 384 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₅N₃O₄: C 65.78; H 6.57; N 10.96. Found: C 65.70; H 6.94; N 11.33.

3-Chloro-*N'*-[2-(6,7-dimethoxy-1-methyl-3,4-dihydro-1*H*-isoquinolin-2-yl)acetyl]benzohydrazide (8e). Yield 69%. ^1H NMR (300 MHz, CDCl₃): δ 1.42 (3H, d, $J = 6.5$ Hz, CH₃), 2.65-3.24 (4H, m, 2 \times CH₂), 3.38 (2H, s, CH₂), 3.840 (3H, s, CH₃), 3.843 (3H, s, CH₃), 3.81-3.89 (1H, m, CH), 6.53 (1H, s, C₅-H), 6.58 (1H, s, C₈-H), 7.27-7.78 (4H, m, aromatic protons), 10.09 (2H, br s, 2 \times NH). ^{13}C NMR (75 MHz, CDCl₃): δ 20.5 (CH₃), 26.6 (CH₂), 45.1 (CH₂), 55.8 (CH₃), 55.9 (CH₃), 56.9 (CH), 57.2 (CH₂), 109.9, 111.3, 125.1, 125.3, 127.7, 129.8, 130.5, 132.1, 132.9,

134.6, 147.3, 147.5 (Ar-C), 163.4 (C=O), 169.3 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3279$; $\nu_{\text{C=O}} = 1701$; $\nu_{\text{C=O}} = 1659$. MS m/z (%): 418/20 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₄ClN₃O₄: C 60.36; H 5.79; N 10.06. Found: C 60.37; H 5.59; N 9.68.

4-Fluoro-N'-[2-(6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)acetyl]benzohydrazide (8f). Yield 80%. Mp 161 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.39 (3H, d, $J = 6.6$ Hz, CH₃), 2.63-3.22 (4H, m, 2×CH₂), 3.32 (1H, d, $J = 17.1$ Hz, CH(H)), 3.38 (1H, d, $J = 16.9$ Hz, CH(H)), 3.82 (6H, s, 2×CH₃), 3.81-3.87 (1H, m, CH), 6.52 (1H, s, C₇-H), 6.56 (1H, s, C₁₀-H), 6.97-7.03 (2H, m, C₃-H and C₅-H), 7.77-7.82 (2H, m, C₂-H and C₆-H), 9.98 (2H, br s, 2×NH). ¹³C NMR (75 MHz, CDCl₃): δ 20.4 (CH₃), 26.6 (CH₂), 45.1 (CH₂), 55.8 (CH₃), 55.9 (CH₃), 57.0 (CH), 57.2 (CH₂), 109.9, 111.3, 115.5 (d, $J = 21.9$ Hz, Ph 3,5-C), 125.1, 127.3 (d, $J = 2.5$ Hz, Ph 1-C), 129.7 (d, $J = 8.8$ Hz, Ph 2,6-C), 130.5, 147.3, 147.5, 164.9 (d, $J = 253.3$ Hz, Ph 4-C), 163.9 (C=O), 169.6 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3254$; $\nu_{\text{C=O}} = 1694$; $\nu_{\text{C=O}} = 1650$. MS m/z (%): 402 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₄FN₃O₄: C 62.83; H 6.03; N 10.47. Found: C 62.52; H 6.41; N 10.18.

N'-[(1E)-(4-Chlorophenyl)methylene]-2-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)acetohydrazide (11a). Yield 24%. Oil. ¹H NMR (300 MHz, CDCl₃): δ 1.39 (3H, d, $J = 6.7$ Hz, CH₃), 2.28-3.19 (4H, m, 2×CH₂), 3.37 (1H, d, $J = 17.1$ Hz, CH(H)), 3.43 (1H, d, $J = 17.1$ Hz, CH(H)), 3.92 (1H, q, $J = 6.7$ Hz, CH), 7.06-7.69 (8H, m, aromatic protons), 8.12 (1H, s, NH), 10.34 (1H, s, N=CH). ¹³C NMR (75 MHz, CDCl₃): δ 19.6 (CH₃), 27.9 (CH₂), 45.5 (CH₂), 57.5 (CH), 57.9 (CH₂), 126.1, 126.4, 127.1, 128.8 (2×CH), 128.9 (2×CH), 132.0, 133.0, 136.4, 138.9, 147.0 (Ar-C), 147.0 (C=N), 167.2 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3207$; $\nu_{\text{C=O}} = 1679$; $\nu_{\text{C=N}} = 1596$. MS m/z (%): 342/44 (M + H⁺, 100). Anal. Calcd for C₁₉H₂₀ClN₃O: C 66.76; H 5.90; N 12.29. Found: C 66.43; H 5.75; N 11.93.

N'-[(1E)-(4-Fluorophenyl)methylene]-2-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)acetohydrazide (11b). Yield 24%. Oil. ¹H NMR (300 MHz, CDCl₃): δ 1.41 (3H, d, $J = 6.7$ Hz, CH₃), 2.78-3.20 (4H, m, 2×CH₂), 3.40 (2H, s, CH₂), 3.93 (1H, q, $J = 6.6$ Hz, CH), 7.03-7.76 (8H, m, aromatic protons), 8.13 (1H, s, NH), 10.33 (1H, s, N=CH). ¹³C NMR (75 MHz, CDCl₃): δ 19.7 (CH₃), 27.9 (CH₂), 45.5 (CH₂), 57.5 (CH), 57.8 (CH₂), 115.8 (d, $J = 21.9$ Hz, Ph 3,5-C), 126.1, 126.4, 127.2, 128.9, 129.5 (d, $J = 8.6$ Hz, Ph 2,6-C), 129.7 (d, $J = 3.5$ Hz, Ph 1-C), 133.0, 138.9, 147.2 (C=N), 164.1 (d, $J = 251.0$ Hz, Ph 4-C), 167.1 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{N-H}} = 3212$; $\nu_{\text{C=O}} = 1682$; $\nu_{\text{C=N}} = 1603$. MS m/z (%): 326 (M + H⁺, 100). Anal. Calcd for C₁₉H₂₀FN₃O: C 70.13; H 6.20; N 12.91. Found: C 69.85; H 6.43; N 12.87.

General procedure for the synthesis of 1-methyl-2-(5-aryl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolines (9a-f)

To a stirred suspension of hydrazide **9** (1 mmol) in dichloromethane (12 mL) was added triphenylphosphine (1.57 mmol), carbon tetrachloride (5 mmol) and triethylamine (1.57 mmol), after which the mixture was heated to reflux for 24 h. The mixture was cooled to room temperature, poured into water (15 mL) and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The residue was chromatographed on silica gel with hexane/acetone 2:1 to yield 1,3,4-oxadiazoles **9** as oils.

1-Methyl-2-(5-phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (9a).

Yield 42%. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.34 (3H, d, *J* = 6.6 Hz, CH₃), 2.69 – 3.17 (4H, m, 2×CH₂), 3.92 (1H, q, *J* = 6.5 Hz, CH), 4.07 (1H, d, *J* = 15.1 Hz, CH(H)), 4.17 (1H, d, *J* = 15.1 Hz, CH(H)), 7.07 – 8.02 (9H, m, aromatic protons). ¹³C NMR (75 MHz, DMSO-*d*₆): δ 19.4 (CH₃), 27.3 (CH₂), 44.6 (CH₂), 47.6 (CH₂), 55.5 (CH), 123.3, 125.6, 125.7, 126.4 (2×CH), 127.0, 128.5, 129.4 (2×CH), 131.8, 135.5, 139.3 (Ar-C), 164.3, 164.4 (C-O-C). IR (KBr, cm⁻¹): ν_{C=N} = 1609. MS *m/z* (%): 306 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₉N₃O: C 74.73; H 6.27; N 13.76. Found: C 74.76; H 6.32; N 13.70.

2-[5-(3-Chlorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1-methyl-1,2,3,4-tetrahydroisoquinoline (9b).

Yield 68%. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.37 (3H, d, *J* = 6.6 Hz, CH₃), 2.71 – 3.20 (4H, m, 2×CH₂), 3.93 (1H, q, *J* = 6.6 Hz, CH), 4.10 (1H, d, *J* = 15.1 Hz, CH(H)), 4.20 (1H, d, *J* = 15.1 Hz, CH(H)), 7.08 – 7.98 (8H, m, aromatic protons). ¹³C NMR (75 MHz, DMSO-*d*₆): δ 19.5 (CH₃), 27.3 (CH₂), 44.7 (CH₂), 47.7 (CH₂), 55.6 (CH), 125.2, 125.3, 125.7, 125.8, 125.9, 127.1, 128.6, 131.5, 131.8, 133.6, 134.0, 139.4 (Ar-C), 163.3, 164.9 (C-O-C). IR (KBr, cm⁻¹): ν_{C=N} = 1606. MS *m/z* (%): 340/42 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈ClN₃O: C 67.15; H 5.34; N 12.37. Found: C 66.78; H 4.99; N 12.19.

2-[5-(4-Fluorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1-methyl-1,2,3,4-tetrahydroisoquinoline (9c).

Yield 77%. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.36 (3H, d, *J* = 6.6 Hz, CH₃), 2.68 – 3.17 (4H, m, 2×CH₂), 3.92 (1H, q, *J* = 6.6 Hz, CH), 4.09 (1H, d, *J* = 15.1 Hz, CH(H)), 4.19 (1H, d, *J* = 15.1 Hz, CH(H)), 7.08 – 8.08 (8H, m, aromatic protons). ¹³C NMR (75 MHz, DMSO-*d*₆): δ 19.5 (CH₃), 27.3 (CH₂), 44.7 (CH₂), 47.7 (CH₂), 55.5 (CH), 116.7 (d, *J* = 22.5 Hz, Ph 3,5-C), 120.1 (d, *J* = 3.6 Hz, Ph 1-C), 125.7, 125.8, 127.1, 128.6, 129.2 (d, *J* = 9.5 Hz, Ph 2,6-C), 133.6, 139.4, 164.1 (d, *J* = 250.2 Hz, Ph 4-C), 163.7, 164.5 (C-O-C). IR (KBr, cm⁻¹): ν_{C=N} = 1610. MS *m/z* (%): 324 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈FN₃O: C 70.57; H 5.61; N 12.99. Found: C 70.32; H 5.33; N 12.74.

6,7-Dimethoxy-1-methyl-2-(5-phenyl-[1,3,4]oxadiazol-2-ylmethyl)-1,2,3,4-tetrahydroiso-

quinoline (9d). Yield 52%. ¹H NMR (300 MHz, CDCl₃): δ 1.45 (3H, d, *J* = 6.6 Hz, CH₃), 2.67 – 3.27 (4H, m, 2×CH₂), 3.83 (6H, s, 2×CH₃), 3.90 (1H, q, *J* = 6.6 Hz, CH), 4.08 (1H, d, *J* = 14.7 Hz, CH(H)), 4.16 (1H, d, *J* = 14.7 Hz, CH(H)), 6.55 (1H, s, C₅-H), 6.56 (1H, s, C₈-H), 7.46-7.55 (3H, m, C₃-H, C₄-H and C₅-H), 8.05-8.08 (2H, m, C₂-H and C₆-H). ¹³C NMR (75 MHz, CDCl₃): δ 20.1 (CH₃), 26.6 (CH₂), 45.2 (CH₂), 48.2 (CH₂), 55.8 (CH), 55.9 (CH₃), 56.0 (CH₃),

109.9, 111.2, 123.7, 125.4, 126.9 (2×CH), 128.9 (2×CH), 130.7, 131.7, 147.3, 147.4 (Ar-C), 164.2, 165.4 (C-O-C). IR (KBr, cm^{-1}): $\nu_{\text{C}=\text{N}}$ = 1610. MS m/z (%): 366 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₃N₃O₃: C 69.02; H 6.34; N 11.50. Found: C 69.35; H 6.28; N 11.23.

2-[5-(3-Chlorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (9e). Yield 82%. ¹H NMR (300 MHz, CDCl₃): δ 1.44 (3H, d, J = 6.6 Hz, CH₃), 2.66 – 3.26 (4H, m, 2×CH₂), 3.82 (6H, s, 2×CH₃), 3.88 (1H, q, J = 6.6 Hz, CH), 4.06 (1H, d, J = 14.8 Hz, CH(H)), 4.15 (1H, d, J = 14.8 Hz, CH(H)), 6.55 (1H, s, C₅-H), 6.56 (1H, s, C₈-H), 7.40-7.51 (2H, m, C₄-H and C₅-H), 7.97-8.04 (2H, m, C₂-H and C₆-H). ¹³C NMR (75 MHz, CDCl₃): δ 20.1 (CH₃), 26.6 (CH₂), 45.2 (CH₂), 48.2 (CH₂), 55.8 (CH), 55.9 (CH₃), 56.1 (CH₃), 110.1, 111.2, 125.0, 125.4, 126.9, 130.3, 130.7, 131.8, 135.1, 147.4, 147.5 (Ar-C), 164.2, 164.6 (C-O-C). IR (KBr, cm^{-1}): $\nu_{\text{C}=\text{N}}$ = 1611. MS m/z (%): 400/02 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₂ClN₃O₃: C 63.08; H 5.55; N 10.51. Found: C 63.33; H 5.45; N 10.63.

2-[5-(4-Fluorophenyl)-[1,3,4]oxadiazol-2-ylmethyl]-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (9f). Yield 87%. ¹H NMR (300 MHz, CDCl₃): δ 1.45 (3H, d, J = 6.6 Hz, CH₃), 2.67 – 3.27 (4H, m, 2×CH₂), 3.83 (6H, s, 2×CH₃), 3.89 (1H, q, J = 6.6 Hz, CH), 4.06 (1H, d, J = 14.7 Hz, CH(H)), 4.14 (1H, d, J = 14.7 Hz, CH(H)), 6.55 (1H, s, C₅-H), 6.56 (1H, s, C₈-H), 7.15-7.22 (2H, m, C₃-H and C₅-H), 8.03-8.10 (2H, m, C₂-H and C₆-H). ¹³C NMR (75 MHz, CDCl₃): δ 20.1 (CH₃), 26.5 (CH₂), 45.1 (CH₂), 48.1 (CH₂), 55.8 (CH), 55.9 (CH₃), 56.1 (CH₃), 109.9, 111.1, 116.3 (d, J = 22.1 Hz, Ph 3,5-C), 120.1 (d, J = 3.3 Hz, Ph 1-C), 125.3, 129.2 (d, J = 9.2 Hz, Ph 2,6-C), 130.6, 147.3, 147.4, 164.7 (d, J = 253.5 Hz, Ph 4-C), 164.2, 164.6 (C-O-C). IR (KBr, cm^{-1}): $\nu_{\text{C}=\text{N}}$ = 1607. MS m/z (%): 384 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₂FN₃O₃: C 65.78; H 5.78; N 10.96. Found: C 65.49; H 5.76; N 10.64.

General procedure for the condensation of 1-amino-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-ones **3** with aromatic aldehydes

To a solution of amine **3** (4 mmol) and 4-substituted benzaldehyde (4.4 mmol) in absolute ethanol (20 mL), 3 drops of piperidine were added and the mixture was refluxed for 5 h. Evaporation of the solvent gave a residue, which was chromatographed on silica gel with hexane/acetone 3:1 (for **10a**, **b**) or dichloromethane/methanol 9:1 (for **10c**) to give the corresponding hydrazones **10**.

1-[(4-Chlorobenzylidene)amino]-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one (10a). Yield 15%. Mp 150 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.89 (3H, s, CH₃), 2.64 – 3.38 (4H, m, 2×CH₂), 3.60 (1H, d, J = 15.2 Hz, CH(H)), 3.68 (1H, d, J = 15.2 Hz, CH(H)), 7.10 – 7.81 (8H, m, aromatic protons), 9.58 (1H, s, N=CH). ¹³C NMR (75 MHz, CDCl₃): δ 23.6 (CH₂), 27.9 (CH₃), 43.9 (CH₂), 52.0 (CH₂), 80.3 (C), 126.5, 127.6, 127.8, 128.5 (2×CH), 128.8, 128.9 (2×CH), 133.2, 133.8, 136.2, 136.9 (Ar-C), 152.3 (C=N), 167.6 (C=O). IR (KBr, cm^{-1}): $\nu_{\text{C}=\text{O}}$ = 1703; $\nu_{\text{C}=\text{N}}$ = 1599. MS m/z (%): 340/42 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈ClN₃O: C 67.15; H 5.34; N 12.37. Found: C 66.96; H 5.44; N 12.48.

1-[(4-Fluorobenzylidene)amino]-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one (10b). Yield 22%. Mp 115 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.98 (3H, s, CH₃),

2.73 – 3.47 (4H, m, 2×CH₂), 3.68 (1H, d, *J* = 15.2 Hz, CH(H)), 3.76 (1H, d, *J* = 15.2 Hz, CH(H)), 7.18 – 7.91 (8H, m, aromatic protons), 9.62 (1H, s, N=CH). ¹³C NMR (75 MHz, CDCl₃): δ 23.6 (CH₂), 27.7 (CH₃), 43.8 (CH₂), 51.9 (CH₂), 80.2 (C), 115.7 (d, *J* = 21.9 Hz, Ph 3,5-C), 126.4, 127.5, 127.7, 128.6, 129.1 (d, *J* = 8.5 Hz, Ph 2,6-C), 131.3 (d, *J* = 2.7 Hz, Ph 1-C), 133.1, 136.8 (Ar-C), 152.6 (C=N), 163.9 (d, *J* = 251.1 Hz, Ph 4-C), 167.3 (C=O). IR (KBr, cm⁻¹): ν_{C=O} = 1703; ν_{C=N} = 1601. MS *m/z* (%): 324 (M + H⁺, 100). Anal. Calcd for C₁₉H₁₈FN₃O: C 70.57; H 5.61; N 12.99. Found: C 70.96; H 5.30; N 12.88.

1-[(4-Chlorobenzylidene)amino]-8,9-dimethoxy-10b-methyl-1,5,6,10b-tetrahydroimidazo[2,1-a]isoquinolin-2(3H)-one (10c). Yield 8%. Oil. ¹H NMR (300 MHz, CDCl₃): δ 1.86 (3H, s, CH₃), 2.87 – 3.34 (4H, m, 2×CH₂), 3.56 (1H, d, *J* = 15.2 Hz, CH(H)), 3.64 (1H, d, *J* = 15.2 Hz, CH(H)), 3.74 (3H, s, CH₃), 3.82 (3H, s, CH₃), 6.53 – 7.71 (6H, m, aromatic protons), 9.68 (1H, s, N=CH). ¹³C NMR (75 MHz, CDCl₃): δ 23.0 (CH₃), 27.8 (CH₂), 43.8 (CH₂), 51.8 (CH₂), 55.6 (CH₃), 55.7 (CH₃), 80.1 (C), 110.2, 110.7, 125.5, 128.1 (2×CH), 128.8, 128.9 (2×CH), 133.7, 136.2, 147.4, 148.4 (Ar-C), 152.0 (C=N), 167.5 (C=O). IR (KBr, cm⁻¹): ν_{C=O} = 1703; ν_{C=N} = 1603. MS *m/z* (%): 400 (M + H⁺, 100). Anal. Calcd for C₂₁H₂₂ClN₃O₃: C 63.08; H 5.55; N 10.51. Found: C 63.28; H 5.25; N 10.63.

Acknowledgements

The authors are indebted to the Research Foundation - Flanders (FWO-Vlaanderen) for financial support of this research.

References

1. For some reviews on isoquinolines, see: (a) Bentley, K. W. *The Isoquinoline Alkaloids*; Harwood Academic Publishers: Amsterdam, 1998. (b) Bentley, K. W. *Nat. Prod. Rep.* **2005**, *22*, 249. (c) Bentley, K. W. *Nat. Prod. Rep.* **2006**, *23*, 444. (d) Chrzanowska, M.; Rozwadowska, M. D. *Chem. Rev.* **2004**, *104*, 3341.
2. Scott, J. D.; Williams, R. M. *Chem. Rev.* **2002**, *102*, 1669.
3. Davidson, B. S. *Chem. Rev.* **1993**, *93*, 1771.
4. For some selected references, see: (a) Worayuthakarn, R.; Thasana, N.; Ruchirawat, S. *Org. Lett.* **2006**, *8*, 5845. (b) Csomós, P.; Martinek, T. A.; Lázár, L.; Fülöp, F. *ARKIVOC* **2003**, (v), 87. (c) Heydenreich, M.; Koch, A.; Lázár, L.; Szatmári, I.; Sillanpää, R.; Kleinpeter, E.; Fülöp, F. *Tetrahedron* **2003**, *59*, 1951. (d) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, T. A. D. *Tetrahedron Lett.* **2001**, *42*, 3943. (e) Ruchirawat, S.; Mutarapat, T. *Tetrahedron Lett.* **2001**, *42*, 1205. (f) Zalán, Z.; Hetényi, A.; Lázár, L.; Fülöp, F. *Tetrahedron* **2005**, *61*, 5287. (g) Nyerges, M.; Töke, L. *Tetrahedron Lett.* **2005**, *46*, 7531. (h) Lee, Y. S.; Kang, D. W.; Lee, S. J.; Park, H. *J. Org. Chem.* **1995**, *60*, 7149. (i) Padwa, A.; Heidelbaugh, T. M.;

- Kuethé, J. T.; McClure, M. S. *J. Org. Chem.* **1998**, *63*, 6778. (j) Katritzky, A. R.; Mehta, S.; He, H.-Y. *J. Org. Chem.* **2001**, *66*, 148. (k) Zhao, B.-X.; Eguchi, S. *J. Chem. Soc., Perkin Trans. 1* **1997**, 2973. (l) Li, W.-D. Z.; Yang, H. *Tetrahedron* **2005**, *61*, 5037. (m) Padwa, A.; Waterson, A. G. *J. Org. Chem.* **2000**, *65*, 235. (m) Sieck, O.; Ehwald, M.; Liebscher, J. *Eur. J. Org. Chem.* **2005**, 663. (n) Kleizienė, N.; Degutytė, R.; Berg, U.; Šačkus, A. *J. Chem. Res.* **2004**, 370.
5. (a) Degutytė, R.; Šačkus, A.; Berg, U. *J. Chem. Res. (S)* **2001**, 540. (b) Valaityte, E.; Martynaitis, V.; Šačkus, A. *Chem. Heterocycl. Comp.* **2004**, *40*, 1465. (c) Beke, D.; Töke, L. *Chem. Ber.* **1962**, *95*, 2122.
 6. Houlihan, W. J.; Manning, R. E. U.S. Patent 3,551,411; *Chem. Abstr.* **1972**, *77*, 48537x.
 7. Dumčiūtė, J.; Martynaitis, V.; Holzer, W.; Mangelinckx, S.; De Kimpe, N.; Šačkus, A. *Tetrahedron* **2006**, *62*, 3309.
 8. For some recent examples on the synthesis of 1,3,4-oxadiazoles, see: (a) Dolman, S. J.; Gosselin, F.; O'Shea, P. D.; Davies, I. W. *J. Org. Chem.* **2006**, *71*, 9548. (b) Levins, C. G.; Wan, Z.-K. *Org. Lett.* **2008**, *10*, 1755.
 9. (a) Thomas, J. Ger. Offen. DE 2403357, 1974; *Chem. Abstr.* **1974**, *81*, 136153. (b) Adelstein, G. W.; Yen, C. H.; Dajani, E. Z.; Bianchi, R. G. *J. Med. Chem.* **1976**, *19*, 1221.
 10. Yale, H. L.; Losee, K. *J. Med. Chem.* **1966**, *9*, 478.
 11. Ghiran, D.; Schwartz, I.; Simiti, I. *Farmacia* **1974**, *22*, 141.
 12. (a) Ezquerra, J.; Builla, J. A. *J. Heterocycl. Chem.* **1986**, *23*, 1151. (b) Wander, A. GB916507, 1963; *Chem. Abstr.* **1963**, *59*, 21707.
 13. Braun, S.; Kalinowski, H.-O.; Berger, S. *150 and More Basic NMR Experiments*; Wiley-VCH: Weinheim, 1998.
 14. Northrop, R. C., Jr.; Russ, P. L. *J. Org. Chem.* **1975**, *40*, 558.
 15. Appel, R.; Kleinstuck, R.; Ziehn, K. D. *Chem. Ber.* **1971**, *104*, 1335.
 16. Wu, C.; Anderson, C. E.; Bui, H.; Gao, D.; Holland, G. W.; Kassir, J.; Li, W.; Wang, J.; Dupre, B. PCT Int. Appl. 078114, 2004; *Chem. Abstr.* **2004**, *141*, 277630.
 17. Borg, S.; Estenne-Bouhtou, G.; Luthman, K.; Csöreg, I.; Hesselink, W.; Hacksell, U. *J. Org. Chem.* **1995**, *60*, 3112 and references cited therein.
 18. Hamlyn, R.; Huckstep, M.; Earnshaw, C. G.; Stokes, S.; Tickle, D.; Allart, B.; Boyd, J. W.; Knutsen, L. J. S.; Lynch, R.; Patient, L. PCT Int. Appl. 082354, 2006; *Chem. Abstr.* **2006**, *145*, 210899.
 19. Gonzales, J. E., III; Termin, A. P.; Martinborough, E.; Zimmerman, N. PCT Int. Appl. 013914, 2005; *Chem. Abstr.* **2005**, *142*, 240421.
 20. Werner, L. H. U.S. Patent 3,480,714, 1969; *Chem. Abstr.* **1970**, *72*, 43485.
 21. Levi, M.; Ivanov, C.; Dryanska, M.; Pavlova, A. *Khim.-Farm. Zh.* **1971**, *5*, 33; *Chem. Abstr.* **1971**, *75*, 35672.